Literature DB >> 22415672

Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.

Young Bin Hong, Jung Soon Kim, Yong Weon Yi, Yeon-Sun Seong, Insoo Bae.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22415672      PMCID： PMC3304537          DOI： 10.1097/MPA.0b013e318230f71a

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  10 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 3.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 4.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.

Authors:  Ioannis Gounaris; Kamarul Zaki; Pippa Corrie
Journal:  JOP       Date:  2010-03-05

6.  A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.

Authors:  A B El-Khoueiry; R K Ramanathan; D Y Yang; W Zhang; S Shibata; J J Wright; D Gandara; H J Lenz
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

Review 7.  Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.

Authors:  Anastasios T Dimou; Konstantinos N Syrigos; Muhammad Wasif Saif
Journal:  JOP       Date:  2010-07-05

8.  A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.

Authors:  Emily Chan; Daniel Mulkerin; Mace Rothenberg; Kyle D Holen; A Craig Lockhart; James Thomas; Jordan Berlin
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

9.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Authors:  Alessandra Blasina; Jill Hallin; Enhong Chen; Maria Elena Arango; Eugenia Kraynov; James Register; Stephan Grant; Sacha Ninkovic; Ping Chen; Tim Nichols; Patrick O'Connor; Kenna Anderes
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

Review 10.  The epithelial-mesenchymal transition: new insights in signaling, development, and disease.

Authors:  Jonathan M Lee; Shoukat Dedhar; Raghu Kalluri; Erik W Thompson
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539
  10 in total
  3 in total

1.  Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.

Authors:  Yeon Jeong Kim; Young Bin Hong; Chi Heum Cho; Yeon-Sun Seong; Insoo Bae
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

2.  Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.

Authors:  Hong-Quan Duong; Young Bin Hong; Jung Soon Kim; Hee-Seok Lee; Yong Weon Yi; Yeon Jeong Kim; Antai Wang; Wenjing Zhao; Chi Heum Cho; Yeon-Sun Seong; Insoo Bae
Journal:  J Cell Mol Med       Date:  2013-07-16       Impact factor: 5.310

3.  Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.

Authors:  Kaidong Liu; Yiding Geng; Linzhu Wang; Huanhuan Xu; Min Zou; Yawei Li; Zhangxiang Zhao; Tingting Chen; Fengyan Xu; Liang Sun; Shuliang Wu; Yunyan Gu
Journal:  Mol Oncol       Date:  2022-07-22       Impact factor: 7.449
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.